Editas Medicine Keeps Moving Forward

Editas Medicine (NASDAQ: EDIT) announced third-quarter 2017 results on Wednesday after the market closed, and shares of the CRISPR gene-editing specialist were down modestly on Thursday in pre-market trading as investors absorbed the news.

But that doesn't mean Editas didn't deliver as promised. This early stage biopharma leader isn't expected to start its first clinical trials until the middle of next year, and management was rightly satisfied with their achievements over the past few months.

Let's put Editas' business under the microscope, then, to better understand how it kicked off the second half of 2017, as well as what investors can expect in the coming quarters.

Source: Fool.com